Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Bristol Myers Squibb (BMY) and Pfizer (PFE) announced a discount of over 40% on their blood thinner drug Eliquis when ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.